Search bioRxiv⌕ Search

Biology subjects

Cioffi, M.

Publications and source records attributed to Cioffi, M..

2 recordsLinked to original sources

Computational Rational Design of Larger AAV Icosahedral Capsids

Adeno-associated virus (AAV) is the preferred viral vector platform in gene therapy. Yet its packaging capacity, about 4.7 kb (kilobases), limits its therapeutic potential and represents a major bottleneck in the field. The packaging capacity of AAV is constrained by its small capsid, which forms a 26-nm-diameter shell assembled from 60 capsid proteins in a T=1 icosahedral architecture. Here, we propose increasing the cargo capacity of AAV vectors by engineering the next possible icosahedral architecture, T=3 (180 capsid proteins), which is predicted to provide a fivefold increase in volume capacity. Oligomers of VP3, the main capsid protein of AAV, were folded using AI-based methods. This identified triangular trimers as the optimal multimer compatible with the tiles of icosahedral lattices in the geometrical theory of capsids. The VP3 trimers were assembled into a T=3 architecture and coarse-grained at 5[A] resolution. It was necessary to introduce 15 deletions (VP3{Delta}15) to accommodate the T=3 curvature. Molecular simulations under physiological conditions demonstrated the stability of the 45 nm-diameter T=3 capsid. Structural analysis measured a five- to sixfold increase in internal volume and estimated a potential upper cargo limit of 35 kb. The engineered VP3{Delta}15 could enable delivery of multicistronic constructs, larger regulatory elements, and CRISPR systems beyond the reach of current AAV vectors. Additionally, the introduced generalized protein design framework could be used to engineer capsids with larger T-numbers and to modify the capacity of other icosahedral delivery systems.

biophysics↗

Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion.

Metastatic disease is the major cause of death from cancer. From the primary tumor, cells remotely prepare the environment of the future metastatic sites by secreted factors and extracellular vesicles. During this process, known as pre-metastatic niche formation, immune cells play a crucial role. Mast cells are hematopoietic bone marrow-derived innate immune cells whose function in lung immune response to invading tumors remains to be defined. We found reduced melanoma lung metastasis in mast cell deficient mouse models (Wsh and MCTP5-Cre-RDTR), supporting a pro-metastatic role for mast cells in vivo. However, due to evidence pointing to their antitumorigenic role, we studied the impact of mast cells in melanoma cell function in vitro. Surprisingly, in vitro co-culture of bone-marrow derived mast cells with melanoma cells showed that they have an intrinsic anti-metastatic activity. Mass spectrometry analysis of melanoma-mast cell co-cultures secretome showed that HMGA1 secretion by melanoma cells was significantly impaired. Consistently, HMGA1 knock down in B16-F10 cells reduced their metastatic capacity in vivo. Importantly, analysis of HMGA1 expression in human melanoma tumors showed that metastatic tumors with high HMGA1 expression are associated with reduced overall and disease-free survival. Moreover, we show that HMGA1 is reduced in the nuclei and enriched in the cytoplasm of melanoma metastatic lesions when compared to primary tumors. These data suggest that high HMGA1 expression and secretion from melanoma cells promotes metastatic behavior. Targeting HMGA1 expression intrinsically or extrinsically by mast cells actions reduce melanoma metastasis. Our results pave the way to the use of HMGA1 as anti-metastatic target in melanoma as previously suggested in other cancer types.

cancer biology↗